Welcome back to This Week in Biotech by Biotech Blueprint, edition 127, covering biotech and pharma news from Nov 12th to Nov 19th, 2026.
I’ll be skipping three editions over the upcoming holidays: Nov 27, Dec 25, and Jan 1.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, please get in touch.
📩 For consulting inquiries, please email me.
👥 If you haven’t already, connect with me on LinkedIn.
🛒 And make sure to check out our MERCH STORE.
VIDEO SUMMARY
THIS WEEK’S KEY TAKEAWAYS 🔑
The FDA lost its commissioner nominee on Tuesday and approved six drugs between Monday and Wednesday. The White House pulled Heidi Overton the night before her committee vote, which hands the choice of a permanent commissioner to a Democratic Senate in January. Meanwhile the review divisions cleared Roche’s breast cancer pill a month early, two myasthenia gravis drugs, a lung cancer drug, and two rare disease firsts. Last week I covered the voucher program getting shelved and wondered whether reviews would slow down without political pressure behind them, but apparently not.
FDA also rejected Summit and Akeso’s ivonescimab, the most watched cancer drug of the past two years. Summit said the problem was the survival miss, but the complete response letter says more than that. 93% of the progression events in the trial came from patients enrolled in China, which left reviewers unable to tell whether the drug works the same way in Americans. The FDA asked Summit to run the trial again, globally.
Neither FDA development this week slowed buying. Pfizer paid $330M upfront for preclinical cell therapies from Shanghai, and Johnson & Johnson paid $2.2B upfront for an eye drug invented at Innovent. A congressional commission then warned that these deals are starting to favor the Chinese side. So the market has split. Chinese molecules are welcome, Chinese pivotal data isn’t, and buyers are paying for the chemistry while budgeting to rerun the trials themselves.
Blackstone is funding $750M of the Phase 3 program for the J&J asset, its second deal like that in two weeks after Pfizer’s. Sanofi, staring at the Dupixent patent expiry, is reportedly weighing a bid for Insmed, a $26B company. Lilly announced its 15th acquisition of the year. The large-cap answer to a patent cliff hasn’t changed: buy late, buy often, and let someone else carry the trial bill.
BIOTECH/PHARMA NEWS 🧬
🔹 The FDA rejected ivonescimab plus chemotherapy for EGFR-mutated lung cancer after targeted therapy. Summit said on Sunday the decision turned on the lack of a statistically significant survival benefit. The letter itself, dated November 13 and published this week, goes further. Reviewers noted that 93% of progression events occurred in patients enrolled in China. That happened because Summit built the global trial by rolling over patients from Akeso’s China-only study and didn’t start Western enrollment until roughly 18 months later. So the events driving the result came almost entirely from one country, and reviewers couldn’t tell whether the benefit transfers. A later analysis showing a hazard ratio of 0.76 in Western patients was labeled exploratory only. The FDA also called the progression-free survival gain modest, 6.8 months versus 4.4, and said it doesn’t outweigh the added toxicity. The FDA asked for a new global trial. Summit fell about 15% Monday, Akeso 22% in Hong Kong. Leerink’s read is that China-only survival data may not support future filings either. The first line HARMONi-3 readout, due by year end, now carries the entire US case.
🔹 The White House pulled Heidi Overton’s nomination late Tuesday, the night before the Senate health committee was due to vote. Republicans hold a one vote majority on that committee, so losing one member would have sunk it. The opposition came from inside the coalition. MAHA figures blamed her for sidelining some of Kennedy’s priorities, and pro-life groups wanted commitments on mifepristone the administration wouldn’t make. Chairman Bill Cassidy disputed the whole account publicly, saying the White House abandoned a viable confirmation path and that he believed she had the votes in committee and on the floor. He also said that with the time left, confirming a permanent commissioner now falls to Senate Democrats, who take the chamber in January. Kyle Diamantas has been acting commissioner since Makary resigned in May, and the withdrawal resets his 210 day clock. Meanwhile the agency kept working. Between Monday and Wednesday it cleared Roche’s Wilserdly, AstraZeneca’s Klygefa, Regeneron’s Livsayis, GSK’s lung cancer drug Nelkarmi, Sanofi’s Infilbray for the neurological symptoms of Type 3 Gaucher disease, and Beren’s Lembaz for infantile-onset Niemann-Pick type C.
🔹 Pfizer will pay Shanghai’s Starna Therapeutics $330M upfront and up to $2.3B in milestones for rights outside Greater China to three preclinical in vivo cell therapies for autoimmune disease. These use RNA to reprogram immune cells inside the body instead of extracting them and engineering them in a factory. It is at least Pfizer’s fifth major China alliance since the start of 2025, and $330M is a large check for programs that haven’t been in a human yet, in a field where Novartis and BMS both paused conventional autoimmune cell therapy trials on safety. The same day, the National Security Commission on Emerging Biotechnology put out a warning about exactly these deals. China has a stated goal of inventing a quarter of the world’s genuinely new drugs by 2030, and the commission’s argument is that getting there would give it enough control over the supply of new medicines to set terms. The second half of the warning is subtler. Every one of these licensing deals teaches the Chinese partner how FDA approval works and how drugs get sold in the US. More than 120 have been signed since the start of 2025. At some point the partner stops needing a partner.
🔹 Sanofi is working with advisers on a possible bid for Insmed, the respiratory drugmaker valued around $26.3B before the report broke. Deliberations are ongoing and a deal could be weeks away. Insmed rose about 21% Thursday, and one analyst put takeover value at $170 to $210 a share. The logic is Dupixent, whose patent expiry leaves a hole that rare disease approvals like Infilbray can’t fill. It was a busy week for buyers generally. J&j agreed to buy Ollin Biosciences for $2.2B upfront plus $1.1B in milestones for an antibody against the same two targets as Roche’s Vabysmo, with Blackstone funding $750M of Phase 3 costs. RBC said the price appears high. Lilly bought Calytrix Bio for up to $1.5B, its 15th acquisition and more than $30B spent this year. Rhythm rose on an unconfirmed report of a Lilly offer near $150 a share, above AstraZeneca’s reported bid.
🔹 Roche’s Wilserdly was approved Nov 16, a month before its deadline, for ER-positive, HER2-negative breast cancer with ESR1 mutations after hormone therapy. It costs $22,500/month and carries unexpected warnings for slow heart rate, though no monitoring requirement. Roche calls it a future top seller and RBC models up to $14B at peak, but nearly all of that depends on earlier-line use, and a second FDA decision is due by Nov 30. Separately, two drugs that block the complement protein C5 arrived in generalized myasthenia gravis within three days. AstraZeneca’s Klygefa is a weekly self injection. Regeneron’s Livsayis, licensed from Alnylam, is the first RNA interference drug approved for an autoimmune disease, dosed four times a year at $410k/year. TD Cowen projects $1.5B at peak and RBC expects a measured start against argenx’s entrenched Vyvgart. Alnylam collects $25M plus royalties. Quarterly dosing is a real advantage, but physicians told RBC they want to watch colleagues use it first.
🔹 CG Oncology’s cretostimogene, an oncolytic virus delivered into the bladder after tumor removal, cut recurrence risk by 68% versus surveillance alone in 367 patients with intermediate-risk or high grade nonmuscle invasive bladder cancer. Hazard ratio 0.32, p<0.0001, at a median 17 months of follow-up. Management and investors had been hoping for 30% to 40%, so this came in well above. No severe drug-related side effects and nobody stopped treatment because of them. There’s no approved drug here, and patients are simply watched until the cancer comes back. Shares rose 12%, to a market value near $8B, and RBC estimates $3.2B in peak US sales. The usual topline caveats apply. No absolute recurrence rates and no subgroup data until the Society of Urologic Oncology meeting on Dec 2. A filing is planned for 2027.
🔹 A cancer vaccine won on survival. Sellas’ galinpepimut-S trains T cells against a protein called WT1 in leukemia cells. In 126 patients with acute myeloid leukemia in second or later remission who couldn’t receive a transplant, median overall survival was 24 months versus 14.7 on best available treatment. Hazard ratio 0.59, p=0.035, a 41% reduction in risk of death, analyzed at the 80th death. Shares rose more than 160% Tuesday and Sellas priced a $150M offering within two days, the same pattern I flagged last week. The trial is small, the p-value isn’t far inside 0.05, and the company hasn’t said what threshold the final analysis had to clear after an earlier interim look. Sellas plans to meet the FDA and could file next year. Small, but it keeps alive the idea that vaccines work best when there’s the least tumor to fight.
🔹 Biogen’s tau-lowering drug diranersen looked better at two years than it did at 18 months. At the Clinical Trials on Alzheimer’s Disease meeting, the twice yearly 60 mg regimen showed a 1.09-point difference on the standard dementia rating scale, a 38% slowing of decline, up from 26%. Biogen says the dose balances benefit and side effects, with no new safety signals, and supports a Phase 3. The trial missed its primary endpoint, which was showing a dose response relationship at week 76. The two year figures come from an open label extension, and by week 96 some patients originally on placebo had received a dose of the drug, a comparison BMO called imperfect. A widening gap is what a disease-modifying drug should produce. It’s also what an unblinded extension tends to produce. Phase 3 decides which one this is. Lilly’s dopamine drug mevidalen failed its Phase 2 at the same meeting.
WATCHLIST 👀
Capricor deramiocel: FDA decision Nov 22 in Duchenne, after a 9-3 negative panel
Roche Wilserdly: second FDA decision, in an earlier treatment setting, by Nov 30
Vertex povetacicept: FDA decision November 30 in IgA nephropathy
CG Oncology: full PIVOT-006 data at SUO December 2
Have a great rest of your week and thanks for reading Biotech Blueprint!

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Front cover image source: FirstWord Pharma

